European Medicines Agency Recommends Ronapreve, Regkirona Covid-19 Treatments for Approval

By Olivia Bugault

The European Medicines Agency on Thursday recommended the authorization of the Ronapreve and Regkirona monoclonal antibody drugs for the treatment of Covid-19.

The agency's recommendation for Ronapreve is for people over 12 years old and weighing at least 40 kilos who don't need supplemental oxygen and that have higher risks of developing severe symptoms, it said. The recommendation is for the treatment of the disease or its prevention, the EMA said. Ronapreve is jointly developed by Swiss pharma Roche Holding AG and the U.S.'s Regeneron Pharmaceuticals Inc.

Regkirona, developed by South Korean biopharma company Celtrion, is recommended for approval for adults also not requiring extra oxygen and whose disease is more likely to become more severe, it said.

The agency will "now send its recommendations for both medicines to the European Commission for rapid legally binding decisions," it said.

Write to Olivia Bugault at [e-mail]

(END) Dow Jones Newswires

November 11, 2021 11:28 ET (16:28 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.